MARKET

IMCR

IMCR

Immunocore Holdings Plc
NASDAQ
28.29
-0.47
-1.63%
After Hours: 28.29 0 0.00% 16:10 06/05 EDT
OPEN
28.76
PREV CLOSE
28.76
HIGH
29.10
LOW
27.67
VOLUME
282.08K
TURNOVER
--
52 WEEK HIGH
40.71
52 WEEK LOW
27.56
MARKET CAP
1.44B
P/E (TTM)
-50.7535
1D
5D
1M
3M
1Y
5Y
1D
ALVO Stock Gains 19% on FDA Resubmission of Biosimilar BLAs
NASDAQ · 2d ago
4 Biotech Stocks Investors Should Watch in 2026
NASDAQ · 2d ago
Immunocore Holdings (IMCR) Gets a Buy from H.C. Wainwright
TipRanks · 4d ago
Analysts’ Top Healthcare Picks: Immuneering (IMRX), Immunocore Holdings (IMCR)
TipRanks · 6d ago
What Immunocore Holdings (IMCR)'s Phase 1 Brenetafusp Data and 160 mcg Dose Choice Means For Shareholders
Simply Wall St · 6d ago
Weekly Report: what happened at IMCR last week (0525-0529)?
Weekly Report · 6d ago
Immunocore Releases Positive Phase 1/2 Data For Brenetafusp In Treating Advanced Cutaneous Melanoma
NASDAQ · 6d ago
Immunocore presents updated results from Phase 1/2 trial of brenetafusp
TipRanks · 05/31 21:25
More
About IMCR
Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a pipeline of clinical-stage programs in oncology and infectious diseases, as well as numerous pre-clinical projects. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-M113V, IMC-I109V, IMC-S118AI, and IMC-U120AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, ovarian, lung, colorectal and others.

Webull offers Immunocore Holdings PLC - ADR stock information, including NASDAQ: IMCR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMCR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMCR stock methods without spending real money on the virtual paper trading platform.